Timberlyne Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoimmune disorders. The company is advancing CM313, a monoclonal antibody targeting CD38, aimed at addressing diseases with high unmet medical needs. Formed through a partnership between Mountainfield Venture Partners and Keymed Biosciences, Timberlyne Therapeutics holds global development and commercial rights for CM313 outside of greater China.